乙肝表面抗原阴性恶性肿瘤患者化疗后乙肝病毒再激活的影响因素

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (701 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the occurrence of the related risk factor hepatitis B virus (HBV) reactivation after chemotherapy in hepatitis B surface antigen (HBsAg) negative patients with malignant carcinoma. Methods A total of five hundred and seventy HBsAg-negative patients with malignant carcinoma who received chemotherapy were recruited during the period of 2006-01 to 2014-12 in Shanghai Corps Hospital of Chinese People’s Armed Police Force. The patients were divided into reactivation group (n=25) and inactivation (n=545) group according to whether the virus was reactivated after chemotherapy. The general information, chemotherapy regimen and index of laboratory examination in both groups were analyzed retrospectively,2 test and logistic regression analysis were performed on potential influencing factors for HBV reactivation. Results The univariate analysis indicated that gender, hepatitis B surface antibody status, e antibody status, core antibody status and whether or no application of immune suppression were statistically significantly different between the two groups. The multivariate non-conditioned logistic regression analysis of these five factors indicated that male (OR=7.700, P＜0.001), hepatitis B surface antibody negative (OR=0.056, P＜0.001), E antibody positive (OR=4.670, P＜0.01) and application of immune suppression (OR=7.978, P＜0.01) were independent risk factors for HBV reactivation after chemotherapy. Conclusions For male, surface antibody negative, core antibody positive and application of immune suppression of HBsAg negative patients with malignant carcinoma, chemotherapy should closely monitor HBV whether reactivation or take early antiviral treatment to prevent HBV reactivation.

Key words： hepatitis B surface antigen malignant carcinoma chemotherapy hepatitis B virus reactivation

Received: 26 April 2016

ZTFLH:

R735

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Yang
	WEI Yan
	JIANG Xuehua
	CHEN Jian
	CHEN Zhiyong
	and YANG Long

Cite this article:

YANG Yang,WEI Yan,JIANG Xuehua等. Influencing factors of hepatitis B virus reactivation after chemotherapy in hepatitis B surface antigen negative patients with malignant carcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(9): 878-880.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I9/878

[1]	Chen W C, Cheng J S, Chiang P H, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy [J]. PLoS One, 2015, 10(6): e0131545.
[2]	Ho E Y, Yau T, Rousseau F, et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy [J]. Hepatol Int, 2015, 9(2): 224-230.
[3]	Tang W, Chen L, Zheng R, et al. Prophylactic effect of lamivudine for lhemotherapy-induced hepatitis B reactivation in breast cancer: a Meta-analysis [J]. PLoS One, 2015, 10(6): e0128673.
[4]	Liu J Y, Sheng Y J, Ding X C, et al. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis [J]. J Formos Med Assoc, 2015, 114(2):164-173.
[5]	Yang Y, Du Y, Luo WX, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy [J]. Cancer Chemother Pharmacol, 2015, 75(4): 783-790.
[6]	Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy[J]. Int J Hematol, 2015, 101(4): 398-404.
[7]	Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B - cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factor and survival [J]. Chin J Cancer, 2015, 34(1): 18.
[8]	Law M F, Lai H K, Chan H N, et al. The impact of hepatitis B virus(HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma[J]. Eur J Cancer Care(Engl), 2015, 24(1): 117-124.
[9]	吴盛喜,许鸿鹞,黄河澄,等.HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J].临床肝胆病杂志,2016,32(1):110-113.
[10]	杨小舟,崔铁军,解莹,等. 核苷类药物对恶性肿瘤患者化疗后乙型肝炎病毒再激活的研究[J]. 中华医院感染学杂志,2016,26(2):289-297.
[11]	Chen K L, Chen J, Rao H L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival [J]. Chin J Cancer, 2015, 34(5): 225-234.
[12]	Elbedewy T A, Elashtokhy H E, Rabee E S, et al. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening[J]. J Egypt Natl Canc Inst, 2015, 27(1): 11-18.
[13]	中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会,中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J].中华血液学杂志,2013,34(11):988-993.